H.C. Wainwright raised the firm’s price target on Ultragenyx (RARE) to $95 from $82 and keeps a Buy rating on the shares post the Q3 report. The firm believes the company’s path to profitability in 2026 is achievable.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.